Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending subcutaneous doses of HM11260C in adults with type 2 diabetes mellitus
2010-019665-28Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Apr 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing HM11260C with Placebo (2 arms). Primary endpoints: Pharmacodynamic effects of HM11260C and Safety and tolerability of HM11260C. Started Apr 2010; status: completed.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-019665-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019665-28.